Drug Profile
Promegapoietin
Alternative Names: Promegapoietin-1aLatest Information Update: 02 Nov 2005
Price :
$50
*
At a glance
- Originator Pfizer
- Class Growth factors
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stem cell mobilisation; Thrombocytopenia
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Stem cell mobilisation in USA (unspecified route)
- 02 Nov 2005 No development reported - Preclinical for Thrombocytopenia in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer